Drug Information Analysis Service

Wolfson JS Hooper DC . Overview of fluoroquinolone safety. Am J Med 1991; 91 (suppl 6A):1535–615.

Schaad UB Wedgwood J . Lack of quinolone-induced arthropathy in children. J Antimicrob Chemother 1992; 30: 414–16.

Maggiolo F Capreoli S Suter F . Risk/benefit analysis of quinolone use in children: The effect on diarthrodial joints. J Antimicrob Chemother 1990; 26: 469–71.

LeBel M . Fluoroquinolones in the treatment of cystic fibrosis: A critical appraisal. Eur J Clin Microbiol Infect Dis 1991; 10: 316–24.

Phillips BM David TJ . Pathogenesis and management of arthropathy in cystic fibrosis. J Roy Soc Med 1986; 79 (suppl 12):44–50.

Schaad UB Wedgwood-Krucko J Guenin K Buehlmann U Kraemer R . Antipseudomonal therapy in cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 1989; 8: 858–65.

Scully BE Nakatomi M Ores C Davidson S Neu HC . Ciprofloxacin therapy in cystic fibrosis. Am J Med 1987; 82 (suppl 4A):196–201.

Meyer H . Ofloxacin in cystic fibrosis. Drugs 1987; 34 (suppl 1):177–9.

Rubio TT . Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diag Microbiol Infect Dis 1990; 13: 153–5.

Black A Redmond AOB Steen HJ Oborska IT . Tolerance and safety of ciprofloxacin in paediatric patients. J Antimicrob Chemother 1990; 26 (suppl F):25–9.

Schaad UB Stoupis C Wedgwood J Tschaeppeler H Vock P . Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J 1991; 10: 723–9.

Schaad UB Sander E Wedgwood J Schaffner T . Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect Dis J 1992; 11: 1047–9.

Schaad UB . Use of quinolones in pediatrics. Eur J Clin Microbiol Infect Dis 1991; 10: 355–60.

Cruciani M Concia E Navarra A Perversi L Bonetti F Arico M Prophylactic co-trimoxazole versus norfloxacin in neutropenic children—perspective [sic] randomized study. Infection 1989; 17: 65–9.

Lang R Goshen S Raas-Rothschild A Raz A Ophir D Wolach B Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: Preliminary experience in 21 children. Pediatr Infect Dis J 1992; 11: 925–9.

Cheesbrough JS Mwema FI Green SDR Tillotson GS . Quinolones in children with invasive salmonellosis (letter). Lancet 1991; 338: 127.

Fontaine O . Antibiotics in the management of shigellosis in children: What role for the quinolones? Rev Infect Dis 1989; 11 (suppl 5):S1145–50.

Samuelson WM Pleasants RA Whitaker MS . Arthopathy secondary to ciprofloxacin in an adult cystic fibrosis patient. Ann Pharmacother 1993; 27: 302–3.

Chysky V Kapila K Hullman R Arcieri G Schacht P Echols R . Safety of ciprofloxacin in children: Worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection 1991; 19: 289–96.

Merskey H , ed. International Association for the Study of Pain (IASP): Subcommittee on taxonomy, classification of chronic pain, description of pain terms. Pain 1986; 3 (suppl):S29–30.

Del Carmen RS . Reflex sympathetic dystrophy. Int Anesthesiol Clin 1991; 29: 79–91.

Bernstein BH Singsen BH Kent JT Kornreich H King K Hicks R Reflex neurovascular dystrophy in childhood. J Pediatr 1978; 93: 211–5.

Schutzer SF Gossling HR . Current concepts review—the treatment of reflex sympathetic dystrophy syndrome. J Bone Joint Surg 1984; 66-A: 625–9.

Gerber JG Nies AS . Antihypertensive agents and the drug therapy of hypertension. In: Gilman AG Rall TW Nies AS Taylor P , eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon, 1990: 784–813.

Kastrup H , ed. Facts and comparisons. St. Louis, MO: Facts and Comparisons, 1993: 763.

Hannington-Kiff JG . Intravenous regional sympathetic block with guanethidine. Lancet 1974; 1: 1019–20.

Hannington-Kiff JG . Relief of Sudeck's atrophy by regional intravenous guanethidine. Lancet 1977; 1: 1132–3.

Glynn CJ Basedow RW Walsh JA . Pain relief following post-ganglionic sympathetic blockade with I.V. guanethidine. Br J Anaesth 1981; 53: 1297–302.

Driessen JJ Van Der Werken C Nicolai PA Crul JF . Clinical effects of regional intravenous guanethidine (Ismelin® in reflex sympathetic dystrophy. Acta Anaesthesiol Scand 1983; 27: 505–9.

Rocco AG Kaul AF Reisman RM Gallo JP Lief PA . A comparison of regional intravenous guanethidine and reserpine in reflex sympathetic dystrophy: A controlled, randomized, double-blind crossover study. Clin J Pain 1989; 5: 205–9.

Blanchard J Ramamurthy S Walsh N Hoffman J Schoenfeld L . Intravenous regional sympatholysis: A double-blind comparison of guanethidine, reserpine, and normal saline. J Pain Sympt Mgmt 1990; 5: 357–61.

Eulry F Lechevalier D Pats B Alliaume C Crozes P Vasseur P Regional intravenous guanethidine blocks in algodystrophy. Clin Rheum 1991; 10: 377–83.

Arnér S . Intravenous phentolamine test: Diagnostic and prognostic use in reflex sympathetic dystrophy. Pain 1991; 46: 17–22.

Centers for Disease Control. Public health service interagency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR 1991; 40 (RR-4):6–17.

Wright TL . Chronic hepatitis B and C. Postgrad Med 1992; 92: 75–82.

Kumar S Pound DC . Serologic diagnosis of viral hepatitis. Postgrad Med 1992; 92: 55–68.

Di Bisceglie AM Martin P Kassianides C Lisker-Melman M Murray L Waggoner J Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506–10.

Davis GL Balart LA Schiff ER Lindsay K Bodenheimer H Perril-Lo R Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized controlled trial. Hepatitis international therapy group. N Engl J Med 1989; 321: 1501–6.

Jacyna MR Brooks MG Loke RHT Main J Murray-Lyon IM Thomas HC . Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis. Br Med J 1989; 298: 80–2.

Cimino L Nardone G Citarella C Perna E Capuano G Budillon G . Treatment of chronic hepatitis C with recombinant interferon alfa. Ital J Gastroenterol 1991; 23: 399–402.

Yoshioka K Kakumu S Hayashi H Shinagawa T Wakita T Ishikawa T Anti-hepatitis C antibodies in patients with chronic non-A, non-B hepatitis: Relation to disease progression and effect of interferon alfa. Am J Gastroenterol 1991; 86: 1495–9.

Brillanti S Masci C Ricci P Miglioli M Barbara L . Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C. Hepatology 1992; 15: 998–1001.

Carreno V Tapia L Ryff JC Quiroga JA Castillo I . Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alfa. J Med Virol 1992; 37: 215–9.

Shoji S Kurata M Makita A Hosoi H Sakai T Takikawa H Clinical study on long-term treatment of chronic hepatitis C with interferon (abstract). Nippon Shokakibyo Gakkai Zasshi 1991; 88: 706–13.

Balmer CM . The new alfa interferons. Drug Intell Clin Pharm 1985; 19: 887–93.

Antonelli G Currenti M Turriziani O Dianzani F . Neutralizing antibodies to interferon-alfa: Relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163: 882–5.

Package insert. Hoffmann-LaRoche: Roferon-A. Nutley, NJ, 1990 Nov.

Package insert. Intron A. Schering: Kenilworth, NJ, 1991 May.